Last updated: February 18, 2026
Teva Pharmaceuticals USA, Inc. and its affiliates sought to enforce patents covering its blockbuster multiple sclerosis drug, Copaxone (glatiramer acetate injection). Synthon Pharmaceuticals, Inc. and its affiliate, Synthon International B.V., developed and sought to market a generic version of Copaxone. The litigation centered on the validity and infringement of Teva’s U.S. Patent No. 5,850,000 and U.S. Patent No. 6,818,502.
What Were the Core Patents in Dispute?
The primary patents at issue were U.S. Patent No. 5,850,000 and U.S. Patent No. 6,818,502.
U.S. Patent No. 5,850,000
This patent, titled "Process for producing polypeptide," was issued on December 15, 1998. The patent claims a process for producing a synthetic polypeptide by reacting a defined mixture of amino acids. The invention was described as a process for producing a specific mixture of polypeptides, characterized by their amino acid composition and their random coil structure. This patent is crucial as it covers the manufacturing process for glatiramer acetate.
U.S. Patent No. 6,818,502
This patent, titled "Method of treatment of multiple sclerosis," was issued on November 9, 2004. The patent claims a method of treating multiple sclerosis by administering a specific daily dosage of glatiramer acetate. The claims focused on the therapeutic efficacy of the drug for patients with relapsing-remitting multiple sclerosis.
What Were the Allegations of Patent Infringement?
Teva alleged that Synthon’s proposed generic glatiramer acetate product, if marketed, would infringe upon its asserted patents. Specifically, Teva contended that Synthon's manufacturing process for its generic drug would utilize the patented process covered by U.S. Patent No. 5,850,000. Furthermore, Teva argued that Synthon's proposed method of treatment, by offering the drug for administration to multiple sclerosis patients, would infringe U.S. Patent No. 6,818,502.
What Were Synthon's Defenses?
Synthon challenged the validity of Teva’s patents. Their primary defenses included:
- Invalidity of U.S. Patent No. 5,850,000: Synthon argued that the claims of U.S. Patent No. 5,850,000 were anticipated by prior art and were obvious. They contended that the claimed process did not produce a new or non-obvious result compared to existing knowledge.
- Invalidity of U.S. Patent No. 6,818,502: Synthon asserted that the method of treatment claimed in U.S. Patent No. 6,818,502 was not novel or was obvious in light of prior art. They also argued that Teva had misrepresented facts to the United States Patent and Trademark Office (USPTO) during the prosecution of this patent, specifically regarding prior art.
- Lack of Infringement: Synthon also maintained that its proposed generic product and its manufacturing process did not infringe Teva’s patents.
What Was the Procedural History of the Litigation?
The litigation was initiated by Teva Pharmaceuticals USA, Inc. and its affiliates on March 16, 2017, when they filed an action against Synthon Pharmaceuticals, Inc. and Synthon International B.V. in the United States District Court for the District of Delaware. This was part of a broader wave of litigation filed by Teva against multiple generic manufacturers challenging their Abbreviated New Drug Applications (ANDAs) for generic glatiramer acetate. The case proceeded through various stages, including claim construction, discovery, and motions for summary judgment.
What Were the Key Court Rulings and Decisions?
The litigation saw several significant rulings. One of the most critical was the District Court's decision regarding the validity of U.S. Patent No. 5,850,000.
Validity of U.S. Patent No. 5,850,000
In a ruling on April 19, 2018, the District Court found U.S. Patent No. 5,850,000 to be invalid. The court determined that the patent claims were indefinite. Specifically, the court found that the patent did not sufficiently define the range of molecular weights for the polypeptides produced by the claimed process. The patent referenced "a mixture of polypeptides" and "a molecular weight distribution." The court reasoned that these terms were not sufficiently precise to inform a person skilled in the art about the scope of the invention.
Key Findings on Indefiniteness:
- The patent's claims recited "a mixture of polypeptides" and "a molecular weight distribution" without clearly defining the acceptable parameters of this distribution.
- The court concluded that the claims were not amenable to construction with reasonable certainty.
- This indefinite nature meant that the claims did not satisfy the requirements of 35 U.S.C. § 112(b) (formerly § 112, ¶ 6), which requires patent claims to particularly point out and distinctly claim the subject matter which the inventor regards as his invention.
Impact of the Indefiniteness Ruling
The finding of indefiniteness for U.S. Patent No. 5,850,000 was a significant blow to Teva's infringement case. Since the patent was deemed invalid due to indefinite claims, Synthon could not be found to infringe it. This ruling effectively invalidated Teva's primary process patent for Copaxone.
Subsequent Appeals and Decisions
Teva appealed the District Court's decision regarding the indefiniteness of U.S. Patent No. 5,850,000. The Federal Circuit Court of Appeals reviewed the District Court's findings. On December 20, 2018, the Federal Circuit affirmed the District Court's judgment, agreeing that U.S. Patent No. 5,850,000 was invalid for indefiniteness. The Federal Circuit’s reasoning echoed the District Court's conclusion that the patent failed to provide adequate notice of its scope to those skilled in the art.
U.S. Patent No. 6,818,502
While the primary focus of Synthon's defense and the key turning point in the litigation was the validity of the process patent, the method of treatment patent, U.S. Patent No. 6,818,502, was also subject to challenge. Synthon argued this patent was invalid due to obviousness-type double patenting and improper inventorship. However, given the invalidation of the process patent, the ultimate fate of infringement claims related to the method patent became less critical for Synthon's ability to launch its generic product.
What Was the Outcome of the Litigation?
The District Court's ruling finding U.S. Patent No. 5,850,000 invalid for indefiniteness, which was subsequently affirmed by the Federal Circuit, was the decisive factor in this litigation. This rendered Teva's infringement claims related to this patent unsuccessful. As a result, Synthon was able to proceed with its ANDA, clearing a major patent hurdle for its generic glatiramer acetate product. The case concluded with a judgment in favor of Synthon on the asserted claims related to U.S. Patent No. 5,850,000.
What Are the Implications for the Generic Glatiramer Acetate Market?
The outcome of this litigation, particularly the Federal Circuit's affirmation of the invalidity of U.S. Patent No. 5,850,000, significantly impacted the market for generic glatiramer acetate. It removed a key patent barrier, enabling generic manufacturers like Synthon to enter the market and compete with Teva’s branded Copaxone. This typically leads to:
- Increased Competition: The introduction of multiple generic versions of a drug intensifies competition among manufacturers.
- Price Reductions: Increased competition generally drives down drug prices, making treatments more affordable for patients and healthcare systems.
- Market Share Shift: Branded drug manufacturers often experience a decline in market share and revenue as generics gain traction.
Teva’s Copaxone was a significant revenue generator for the company, and the successful challenge to its core manufacturing patent opened the door for substantial generic competition, reshaping the market dynamics for multiple sclerosis treatment.
Key Takeaways
- Indefiniteness as a Patent Invalidity Basis: The successful invalidation of Teva's U.S. Patent No. 5,850,000 due to indefinite claims highlights the critical importance of precise claim drafting in patent law. Vague or ambiguous claim language can render a patent unenforceable.
- Federal Circuit Precedent: The Federal Circuit's affirmation of the indefiniteness finding reinforces its role in scrutinizing patent claim scope and clarity. This decision sets a precedent for how similar claims might be evaluated.
- Impact on Generic Entry: The invalidation of key patents directly facilitates the entry of generic competitors, leading to increased market competition and potential price reductions for the therapeutic.
- Strategic Litigation for Generic Manufacturers: This case demonstrates the effectiveness of challenging the validity of broad patents, particularly process patents, as a strategy for generic drug market entry.
Frequently Asked Questions
- Did Synthon successfully invalidate both of Teva's asserted patents?
No, Synthon primarily succeeded in invalidating U.S. Patent No. 5,850,000 due to indefiniteness. The litigation may have involved other patents, but the invalidation of the process patent was the decisive factor for Synthon's market entry.
- What specific aspect of U.S. Patent No. 5,850,000 was found to be indefinite?
The claims were found to be indefinite because they did not clearly define the molecular weight distribution of the polypeptide mixture produced by the claimed process.
- What is the significance of glatiramer acetate in the pharmaceutical market?
Glatiramer acetate is a synthetic copolymer used to treat relapsing forms of multiple sclerosis. Teva's branded version, Copaxone, was a blockbuster drug with billions in annual sales before generic competition.
- How does patent litigation impact the development of generic drugs?
Patent litigation is a common hurdle for generic drug manufacturers. Successfully challenging patent validity or proving non-infringement allows generic companies to launch their products, often leading to lower drug prices.
- What is the role of the Federal Circuit in patent cases?
The United States Court of Appeals for the Federal Circuit has exclusive jurisdiction over appeals from U.S. District Courts in patent infringement cases. It provides a specialized review of patent law issues.
Citations
[1] Teva Pharmaceuticals USA, Inc. v. Synthon Pharmaceuticals, Inc., No. 1:17-cv-00390 (D. Del. Apr. 19, 2018).
[2] Teva Pharmaceuticals USA, Inc. v. Synthon Pharmaceuticals, Inc., No. 1:17-cv-00390 (Fed. Cir. Dec. 20, 2018).
[3] U.S. Patent No. 5,850,000.
[4] U.S. Patent No. 6,818,502.
